AngioDynamics is like a specialized Boston Scientific, focusing on peripheral vascular disease treatments and unique tumor ablation technologies.

AngioDynamics is like a more specialized Becton Dickinson (BD), providing advanced tools for vascular access, disease management, and targeted tumor destruction.

• NanoKnife Ablation Systems: Devices designed for the surgical ablation of soft tissues.
• Microwave & Radiofrequency Ablation Systems: Systems used for ablating solid cancerous or benign tumors.
• Oncology & Surgical Support Products: Includes tract sealant systems, endorectal balloons, and vaginal balloon packing systems for use in oncology and surgical settings.
• Diagnostic & Interventional Devices: Products such as angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.
• Vascular Interventions & Therapies Products: Devices addressing thrombus management, atherectomy, peripheral vascular disease, and venous insufficiency.
• Vascular Access Devices: A range of peripherally inserted central catheters (PICC), midline catheters, implantable ports, and dialysis catheters for delivering short-term drug therapies into the central venous system.

• Hospitals and Clinics: These are the primary institutional customers where professional healthcare providers such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses utilize AngioDynamics' products for patient treatment.
• Medical Distributors: AngioDynamics sells its products through "distributor relationships," indicating that medical distributors are direct customers who then facilitate the sale and delivery of these products to various healthcare providers and facilities.
• Specialized Healthcare Facilities and Group Practices: This category includes specialized centers focusing on areas like peripheral vascular disease, oncology, or surgical settings, which may operate independently or as part of larger networks and directly purchase devices for their specific needs.

Jim Clemmer, President and Chief Executive Officer

Jim Clemmer joined AngioDynamics in April 2016 and brings over 25 years of leadership within the healthcare industry. Prior to AngioDynamics, he served as president of the $1.8 billion medical supplies segment at Covidien plc., where he directed strategic and day-to-day operations for global business divisions. He also managed global manufacturing, research and development, operational excellence, and business development. Before Covidien, Clemmer was group president at Kendall Healthcare, where he managed the U.S. business across five divisions and developed the strategic plan for the Medical Supplies segment before its spin-off from Tyco. He began his career at Sage Products, Inc. Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging.

Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer

Stephen A. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having served as Interim Chief Financial Officer since October 2019. He joined AngioDynamics in June 2008 as Corporate Counsel and subsequently served as Senior Vice President and General Counsel. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. He began his career with Cadwalader, Wickersham & Taft LLP in the firm's Mergers and Acquisitions and Securities Group.

Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International

Laura Piccinini joined AngioDynamics in June 2021, bringing more than 25 years of experience in leadership roles in the Medical Device/Technology industry, with an extensive background in respiratory care. Most recently, she served as CEO and a member of the Board of Directors for Respiratory Motion, Inc. She was also Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Earlier in her career, Ms. Piccinini served as President of EMEA at both Covidien and Stryker.

Chad T. Campbell, Senior Vice President and General Manager for AngioDynamics' Oncology and Interventional Devices Global Business Units

Chad T. Campbell joined AngioDynamics in May 2016. In his role, he oversees global commercialization of the Oncology and Interventional Devices global business unit portfolios. Mr. Campbell joined AngioDynamics from Medtronic, where he served as Vice President of Marketing for the Patient Care and Safety business. He previously served as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic). During his tenure at Covidien, Mr. Campbell also held roles including Director of Marketing, Area Vice President of Sales, and other sales & marketing positions.

Key Risks for AngioDynamics

1. Regulatory Hurdles and Reimbursement Challenges: As a medical device company, AngioDynamics is heavily reliant on obtaining and maintaining regulatory approvals for its diverse product portfolio, including devices for peripheral vascular disease, vascular access, and oncology applications. Changes in regulatory policies by bodies such as the FDA, or in domestic and foreign healthcare reforms and government regulations, could delay product introductions or necessitate costly compliance measures. Furthermore, evolving healthcare reimbursement policies and pricing pressures from group purchasing organizations directly impact the market acceptance and profitability of AngioDynamics' products, affecting demand and revenue generation.
2. Intense Competition and Rapid Technological Obsolescence: AngioDynamics operates in highly competitive markets with numerous participants, some of whom possess substantially greater financial and technological resources. The company faces ongoing pressure from competitors' technological advancements, new product introductions, and aggressive pricing strategies. The failure to continuously innovate, develop new products, or gain market acceptance for its offerings could lead to a loss of market share and reduced sales.
3. Product Liability Claims and Recalls: Given that AngioDynamics designs, manufactures, and sells medical, surgical, and diagnostic devices used in critical healthcare settings, there is an inherent risk of product defects or malfunctions. Such issues could lead to patient injury, costly product recalls, and significant product liability claims, which could severely impact the company's financial performance, reputation, and ability to sell its products.

AngioDynamics (ANGO) operates in several medical device markets, with the following addressable market sizes identified for their main products and services:

• Microwave Tissue Ablation Systems: The global microwave ablation market was valued at approximately USD 437.1 million in 2024 and is projected to reach USD 962.1 million by 2030. North America held the largest revenue share of 31.2% in the global market in 2024.
• Radiofrequency Ablation Products (Oncology/Tumor Ablation): The global radiofrequency ablation tumor ablation market was valued at USD 703.7 million in 2025 and is estimated to grow to USD 2,051.1 million by 2033. North America was the largest revenue-generating market in 2025. The broader global radiofrequency ablation devices market (including various applications) was estimated at USD 4.3 billion in 2022 and is projected to reach USD 10.5 billion by 2030.
• Thrombus Management: The global thrombin market was valued at USD 662.96 million in 2024 and is poised to grow to USD 1,073.4 million by 2033. North America is the largest market, accounting for approximately 45% of the global share.
• Atherectomy Devices: The global atherectomy devices market size was USD 794.6 million in 2024 and is expected to grow to USD 1.6 billion by 2034. The U.S. atherectomy devices market alone was valued at USD 432.6 million in 2024. North America dominates the atherectomy devices market, holding a 42.4% share in 2025.
• Peripheral Products (Peripheral Vascular Disease Treatment): The global peripheral arterial disease treatment market was valued at USD 2.95 billion in 2024 and is projected to reach USD 6.11 billion by 2034. North America dominated this market with a 39% share in 2024. The global peripheral vascular devices market was valued at USD 9.55 billion in 2025 and is projected to reach USD 13.22 billion by 2031.
• Venous Insufficiency: The chronic venous insufficiency treatment market in the 7MM (United States, EU4, UK, and Japan) was estimated at USD 2,652 million in 2025 and is projected to reach USD 5,951 million by 2034. The U.S. accounted for the largest market size for chronic venous insufficiency in 2023.
• Peripherally Inserted Central Catheters (PICC): The global peripherally inserted central catheters market size was valued at USD 1.25 billion in 2025 and is projected to grow to USD 3.23 billion by 2034. North America was the largest region in the PICC market in 2025 and is expected to hold the largest share of 46.65% in 2023.
• Midline Catheters: The global midline catheter market size was estimated at USD 3.01 billion in 2024 and is projected to reach USD 4.74 billion by 2032. North America dominated the midline catheters market with the largest revenue share of 40.31% in 2024.
• Implantable Ports: The global adult implantable port market size was USD 3.53 billion in 2025 and is projected to grow to USD 7.01 billion by 2032. North America is expected to dominate the adult implantable port market with a market share percentage valuation of around 37%. Another estimate for the global implantable port market was slightly over USD 370 million in 2023, expected to reach about USD 450 million.
• Dialysis Catheters: The global dialysis catheters market size was valued at around USD 1 billion in 2023. The hemodialysis catheters segment recorded USD 927.7 million in 2023. The global hemodialysis catheters market size was USD 1.14 billion in 2025 and is predicted to increase to approximately USD 2.08 billion by 2035. North America's dialysis catheters market accounted for USD 408.8 million in revenue in 2023.

AngioDynamics (ANGO) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and product performances:

1. Strong Performance and Expansion of Med Tech Portfolio: The company's Med Tech segment, identified as its growth engine, is expected to continue driving revenue. This includes sustained growth from the Auryon peripheral atherectomy platform, which has consistently shown double-digit year-over-year growth. The thrombus management platform, particularly the AlphaVac mechanical thrombectomy system, is also a significant contributor, with AlphaVac revenues increasing substantially and projected to surpass AngioVac in the coming years due to a larger market opportunity for pulmonary embolism (PE). AngioDynamics is further investing in this area by expanding its dedicated PE sales force and achieving regulatory milestones like IDE approvals for APEX-Return and PAVE studies, and 510(k) clearance for a modified AlphaVac system. Additionally, the NanoKnife irreversible electroporation platform is experiencing strong growth, largely fueled by increased prostate procedures and the implementation of a new CPT code, which is expected to further boost adoption.

2. International Market Expansion: AngioDynamics is actively pursuing and experiencing growth in international markets. The company's international business demonstrated double-digit growth, with efforts like the third international clinical life symposium leading to increased interest in its Med Tech products globally. Notably, the CE Mark approval for its Auryon platform has facilitated its contribution to international revenue. The company is strategically focused on expanding its products geographically.

3. Customer Base Expansion and Increased Utilization: Growth in AngioDynamics' customer base, particularly within Office-Based Labs (OBLs) and hospital settings, is expected to enhance revenue. This expansion, coupled with increased utilization of its products in existing accounts, positively impacts average selling prices (ASP) and overall revenue.

4. Strategic Portfolio Shift and Pricing Actions: The company has undertaken a strategic reshaping of its portfolio, moving away from slower-growth, commodity-oriented markets to focus on higher-growth, higher-margin Med Tech categories. This strategic shift aims to improve the overall revenue mix. Furthermore, AngioDynamics has implemented pricing actions that have contributed to gross margin improvement and are expected to continue enhancing revenue.